Ginkgo Bioworks Holdings, Inc.
DNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGinkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. At a $468.0M market cap, Ginkgo Bioworks Holdings, Inc. ranks as a small-cap company within healthcare. It operates through the Cell Engineering and Biosecurity segments.
Market Cap
$468.0M
Beta
1.77
P/E (TTM)
—
P/E (Fwd)
-2.40
EPS (TTM)
$-5.33
EPS (Fwd)
$-2.90
ROE
-59.9%
ROA
-16.7%
Cash
$302.2M
Total Debt
$404.1M
Free CF
-$72.4M
52W Change
-35.4%
Annual Financials
Cash vs Debt
Where DNA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, DNA finished 11.25% below its 150-day moving average ($8.18) and 13.05% below its 200-day moving average ($8.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DNA overbought or oversold?
At the August 28, 2026 close, DNA's RSI(14) was 43.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, DNA has $302.2M in cash with $404.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$72.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -59.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $477.7M (2022) to $170.2M (2025), a 64% decline worth watching.
A beta of 1.77 means DNA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing DNA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.